Theralink® Technologies (“Theralink”) is a CLIA-certified, proteomics-based, molecular profiling and precision medicine company located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and laboratory developed test (LDT), Theralink’s technology targets multiple areas of oncology and drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity.
Theralink Technologies, Inc., formerly Avant Diagnostics, Inc. was founded in 2009.
In June of 2020, OncBioMune Pharmaceuticals, Inc. (OTC: OBMP) purchased all the assets of Avant Diagnostics, Inc. In September of 2020, the corporate name was officially changed to Theralink Technologies, Inc.
15000 West 6th Avenue, Suite 400
Golden, CO 80401
In June of 2020, OncBioMune Pharmaceuticals, Inc. (OTC: OBMP) purchased all the assets of Avant Diagnostics, Inc and began operating as the public company, Theralink Technologies, Inc. The official corporate name change to Theralink was completed in September 2020.
OncBioMune Pharmaceuticals, Inc. had begun trading on the OTCQB under the ticker “OMBP” on February 8, 2013.
Theralink trades on the OTC Market under the ticker symbol “OBMP.”
You can purchase shares in the Company through a registered broker-dealer of your choice. You cannot purchase units directly from the Company. For information about investing in stocks, you may want to consult a financial professional to explain to you the risks and suitability when investing.
We do not offer a direct stock purchase or dividend reinvestment program.
Theralink does not anticipate paying any cash dividends in the foreseeable future.
Our fiscal year end is September 30. The Company’s quarterly periods conclude on December 31, March 31, June 30, and September 30.
Salberg & Company, P.A.
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave, Suite 106
Encinitas, CA 92024
619-664-4780
Please submit investor questions here.